Objectives Chikungunya virus (CHIKV), transmitted to humans from infected mosquitoes, causes acute fever, arthralgia and rash. There is increasing evidence that it also causes longer-term rheumatic symptoms. In a circumscribed part of Mauritius where infectivity was high, a cohort of inhabitants was surveyed with the objectives of assessing the prevalence of and risk factors for chronic musculoskeletal symptoms and for a rheumatoid arthritis-like condition at 27.5 months after initial infection. Methods Participants were recruited May-November 2008 and invited to complete a questionnaire. CHIKV was diagnosed clinically. The primary outcomes for the analyses were (a) self-reported ongoing musculoskeletal symptoms and (b) fulfilment of modified diagnostic criteria for rheumatoid arthritis. Risk factors for these outcomes were explored in univariate analyses using logistic regression. Subsequently, multivariate logistic regression was used to identify factors that were independently associated with the outcomes. Results 173 individuals were identified with CHIKV, of whom 136 (78.6%) reported persisting musculoskeletal symptoms 27.5 months after infection. Persistent symptoms were associated with older age at time of infection, female gender and baseline symmetrical distribution of joint symptoms. We found that 5% of those infected with CHIKV fulfilled a modified version of the American College of Rheumatology criteria for rheumatoid arthritis 27.5 months after infection. Conclusions CHIKV is associated with a high prevalence of persistent rheumatic symptoms. Physicians need to be aware of CHIKV as a cause of acute and chronic rheumatic symptoms.
INTRODUCTION
Chikungunya fever is an acute febrile illness caused by the chikungunya virus (CHIKV), an arbovirus belonging to the genus Alphavirus (Togaviridae family). The word chikungunya means 'that which bends up' referring to the stooped posture of patients with severe arthralgia. 1 CHIKV is arthropod-borne and transmitted to humans through bites from infected Aedes mosquitoes. The first documented epidemic occurred in Tanzania in 1952-1953, 2 and, since that time, CHIKV has caused large outbreaks affecting millions in Africa, South-East Asia and around the Indian Ocean. CHIKV has rarely been reported in non-tropical countries, and, when seen in Europe (cases have been reported in UK, Belgium, Czech Republic, Norway, Poland, France, Spain and Germany), it occurred in travellers returning from the tropics. However, there have been recent reports of local CHIKV outbreaks in Europe, including one in Italy 3 where local transmission resulted in 205 cases. 4 With globalisation, the disease may gain a foothold in other European countries that contain well-adapted mosquito vectors.
CHIKV has several similarities to dengue fever infection. Transmitted by the same mosquito vectors, they occur in the same geographical regions and cause similar acute presentations. The incubation period ranges from 1 to 12 days (average 2-4 days) followed by an abrupt onset of high fever, rash, headache, photophobia, back pain, myalgia and arthralgia. Symptoms of diarrhoea and abdominal pain may occur, and neurological manifestations (vertigo, encephalitis, meningoencephalitis, febrile seizures) have been reported among those hospitalised with acute infection, particularly children. Other clinical manifestations including cardiovascular diseases, pneumonia, prerenal failure and respiratory failure have been observed. Haemorrhagic complications are, however, rare, providing a distinction from dengue fever. A recent comparative epidemiological study in Malaysia suggested that patients infected with CHIKV were significantly older and more likely to be female than those with dengue infection. 5 A case fatality rate of 1 in 1000 has been estimated for CHIKV, with greatest mortality among neonates and the elderly. Overall, polyarthralgia is the most common-and disabling-symptom of acute CHIKV, affecting 73-99%. Usually symmetrical, it predominantly affects hands, wrists, elbows, knees and toes but may affect any joint and is commonly associated with periarticular swelling. Asymptomatic infections are rare. CHIKV is normally diagnosed on the basis of clinical, epidemiological and laboratory criteria. In the setting of a known outbreak, diagnosis may be confirmed by detection of viral nucleic acid in the serum of patients with acute symptoms using reverse transcriptase PCR. In samples obtained later, the diagnosis is confirmed by the presence of an immune response using immunofluorescence or ELISA. A specific IgM response is usually detectable 2-7 days after onset of fever. IgG antibody response may be detectable as soon as 2 days after onset but typically is detectable after >6 days and may persist for years. The only recommended treatment for CHIKV arthralgia is non-steroidal antiinflammatory drugs. Various other treatments, including chloroquine, corticosteroids, ribavirin, type I interferon α and CHIKV antibodies, have been suggested, but little evidence is yet available from clinical trials.
Physicians should be aware of CHIKV for two reasons: first, as a differential diagnosis for an abrupt onset of high fever (often exceeding 38.9°C), rash and arthralgia, particularly among those recently returned from travel; second, there is increasing evidence that CHIKV infection causes persistent musculoskeletal symptoms, and in a proportion of cases, may cause chronic symmetrical polyarthritis resembling rheumatoid arthritis (RA). 6 7 Simon et al 8 followed up 47 patients with imported CHIKV infection in Marseilles and found that 82.6% had chronic joint symptoms and tenosynovitis at 10 days, and 48% still had ongoing joint symptoms at 6 months. A retrospective cohort study of 147 CHIKV confirmed cases in Reunion, a French territory in the Indian Ocean, reported joint symptoms in 57% of participants at 15 months. Persistence of joint symptoms was associated with older age, severe initial arthralgia and co-existing osteoarthritis. 9 Borgherini et al 10 followed up 88 CHIKV-confirmed patients also in Reunion and found persistent arthralgia in 63.6% after 18 months. Similar findings were reported after 18 months by Gérardin et al, 11 who found that 43% of CHIKV-infected participants reported musculoskeletal pain compared with 17% of seronegative ones.
Mauritius is a tropical island nation in the Indian Ocean 2000 km off the South East coast of the African Continent (box 1). There have been two CHIKV outbreaks in Mauritius: a circumscribed one in 2005 and a generalised one in 2006. The CHIKV outbreaks appeared to have originated in Kenya 12 before reaching the Indian Ocean islands and spreading to India and South East Asia. 13 Here we present the results of an epidemiological study on a cohort of CHIKV-infected inhabitants >2 years after the acute symptoms. The aims were to: define the prevalence and impact of chronic musculoskeletal symptoms at 27.5 months; explore factors predisposing to chronicity; investigate the proportion of cases with an RA-like syndrome fulfilling the 1987 American College of Rheumatology criteria for a diagnosis of RA. 14 
METHODS

Sampling frame
This study was set in the Rivière du Rempart district of Mauritius, chosen because this district had high (>50%) CHIKV infectivity levels during the 2006 outbreak. 15 Sampling took place in numerous different localities chosen to maximise the availability of the complete range of ages and genders to participation including village centres, workplaces, sports centres, women's centres and local health centres.
Subjects
Subjects were included if they were aged>18 years, reported having been acutely ill during the epidemic in 2006, and were able to give written, informed consent.
Sample size
Using the Chikungunya Case calculator, devised by Ramchurn et al, 15 an estimated 55.7% of residents in the Rivière du Rempart District were likely to have been infected in the 2006 outbreak (∼59 000 individuals). Existing epidemiological studies suggest that musculoskeletal symptoms persist in 44-64% of CHIKV-infected individuals after 6 months. 6 7 9-11 Therefore, we estimated that a sample size of 200 would yield 120 CHIKV-infected subjects, of whom ∼50-77 would have persistent symptoms (cases) and the remainder would not (controls), allowing sufficient power to detect differences in risk factors at the 95% CI ( p<0.05).
Questionnaire
A detailed questionnaire was developed including demographics, details of infection with CHIKV, medical care and treatment received at baseline, joint symptoms at onset, residual joint symptoms, comorbidities and impact of chronic joint symptoms using the Arthritis Impact Measurement Score (AIMS)-2 SF 16 17 selected as a validated tool for assessment of the impact of arthritis.
Data collection
Data collection was undertaken by one trained observer (KE) May-November 2008. At each site, the investigator explained that this was a survey and that we were interested in obtaining responses from anyone who had been acutely ill during the CHIKV epidemic of 2006. Written information leaflets were circulated emphasising that we were interested in anybody who had been infected, whatever their age, gender or current health status. Written, informed consent was obtained. The questionnaire was administered in a structured interview taking 40 min.
Diagnosis of CHIKV
In Mauritius, it is official policy that testing for CHIKV-specific antibodies can only be performed in selected facilities. For the purposes of this study therefore it was not possible to perform serological testing because of these official restrictions. However, during an established CHIKV outbreak, it is not held essential that all cases be serologically proven. It has been shown that most infected individuals show symptoms, with only ∼5% of cases being asymptomatic. 18 Therefore, during an outbreak, presentation with the classical CHIKV disease triad of fever, arthralgia and rash is sufficient to diagnose the condition clinically, 19 and, furthermore, there are data to suggest that abrupt presentation with any two of these is sufficient. 20 Hence for the purposes of this study, participants were eligible for inclusion if they described an acute illness associated with at least two of these three symptoms.
Rheumatoid arthritis
The 1987 American College of Rheumatology (ACR) criteria for the diagnosis of RA require more than four of the following: morning stiffness; arthritis in more than three joint areas; arthritis of hand joints; symmetrical arthritis; rheumatoid nodules (validated by physician); rheumatoid factor and radiographic changes.
14 The methodology of this study did not allow
Box 1
Mauritius was first 'discovered' by Portuguese settlers in the 1500s. Colonised subsequently by Portuguese, Dutch, French and British settlers, it became formally independent in 1968 and has been a Republic since 1992. Its current population is 1.3 million people. Its economy is based on tourism, textiles, finance and sugar. The University of Mauritius in Réduit is the Republic's oldest University dating back to 1972. It has around 14 000 students and is expanding rapidly. The Faculty of Science is one of its five principal faculties.
assessment of serology for rheumatoid factor or inflammatory markers or radiographic changes and therefore a diagnosis of 'RA' at 27.5 months after infection was made in the presence of four out of the five remaining ACR criteria: pain at follow-up in all three sites of the hands and wrists ( proximal interphalangeal joints, metacarpophalangeal joints and wrists); swelling at follow-up in more than three predefined skeletal sites (hands, wrists, elbows, knees, ankles, feet); symmetrical distribution; rheumatoid nodules; or early morning stiffness. The trained observer was not medically qualified but was trained to localise the anatomical sites of pain and swelling and validate the presence of nodules by visual inspection.
Data analysis
Data were analysed using SPSS V.17.0. The means of the AIMS-2 SF components, after recoding and calculation, were calculated for each component of the questionnaire. The primary end points for the analyses were (a) the reporting of current musculoskeletal symptoms and (b) fulfilling the modified diagnostic criteria for 'RA'. Continuous variables were analysed using Student t tests, and categorical variables using χ 2 tests. Risk factors for the principal outcomes were explored in univariate analyses using logistic regression. Potential risk factors considered were gender, age, ethnicity, symptoms at presentation, comorbidities and treatment received. Subsequently, multivariate logistic regression was used to identify factors that were independently associated with the outcomes, with factors selected for inclusion if they demonstrated some association ( p<0.10) in univariate analyses.
Ethics approval was obtained from the University of Mauritius Research Ethics Committee on 7 March 2007.
RESULTS
A total of 195 subjects consented to participate, of whom 173 (89%) could be clinically diagnosed with CHIKV (table 1) . In total, these comprised 30 men and 143 women, mean age 52.1 years, mostly (89%) Indo-Mauritian origin. One hundred and seventy (98%) reported the classical triad of symptoms at baseline and three reported rash and fever without arthralgia. The outbreak occurred February-November 2006, and the majority (67%) had succumbed to CHIKV in March or April 2006 (median duration since infection 27.5 months).
Persistent musculoskeletal symptoms
Out of 173 CHIKV-infected subjects, 136 (79%) reported persistent musculoskeletal symptoms. All reported joint pains, 93% fatigue, 90% joint pain on exertion, 89% morning stiffness, 85% muscle weakness, and 77% paraesthesiae. When asked to rate the severity of their symptoms, only 7% reported that the severity was <3 on a Visual Analogue Scale (VAS); 67% rated the severity between 4 and 7 on the VAS, and the remaining 26% rated it 7-10. Thirty-five per cent defined their joint pains as present 'all the time', and 65% as 'intermittent'. Table 1 compares the characteristics of the 136 individuals who reported persistent musculoskeletal symptoms with the 37 who reported recovery. Persistent symptoms were significantly more likely among those who were older at the time of infection ( p<0.0001) and among women (OR 5.5, 95% CI 2.4 to 12.8) ( p<0.0001). Recall of swollen joints (OR 2.8, 95% CI 1.3 to 5.9), stiff joints (OR 4.2, 95% CI 1.2 to 14.7), and involvement of joints in a symmetrical distribution (OR 50, 95% CI 11.5 to 200) at the time of infection were significantly associated with persistent symptoms. Moreover, having all three symptoms at baseline was significantly associated with persistence (OR 5.4, 95% CI 1.2 to 23.8). However, having joint pains without either swelling or stiffness was associated with a better likelihood of recovery (rate of recovery 51% vs 24%) after 27.5 months (OR 0.3, 95% CI 0.14 to 0.62).
The results of the multivariate logistic regression modelling suggested that older age ( p=0.005), female gender ( p=0.092), baseline joint pains in a symmetrical distribution ( p<0.0001) and having attended more than two healthcare providers at baseline ( p<0.0001) were factors independently significantly associated with persistent musculoskeletal symptoms at follow-up.
Fulfilment of 1987 ACR criteria for a diagnosis of RA
Of the 136 subjects with persistent joint symptoms at the time of the survey, 106 (78%) reported early morning stiffness, 103 (76%) a symmetrical distribution of joint pain, 10 (7%) were observed to have subcutaneous nodules, 87 (64%) described pain in three sites at the hand and wrist, and 12 (9%) described joint swelling in more than three of the relevant skeletal sites. Therefore, 10 subjects could be distinguished who would fulfil the predefined modified criteria for RA. These were all female, of Indo-Mauritian origin and mean age of 60.4 years. Table 2 shows a comparison of the AIMS-2 scores for those with 'RA' compared with those with persistent musculoskeletal symptoms. In all domains except social interaction, those with 'RA' were more disabled.
As shown in table 3, compared with those not fulfilling the modified criteria, those with 'RA' were on average 18 years older (60.4 years vs 42.5 years, p=0.001) and all were female. A symmetrical distribution of joint symptoms at the time of CHIKV infection was significantly associated with 'RA' (p<0.0001), and reporting pain, swelling and stiffness at baseline was also significantly associated (OR 7.5, 95% CI 1.1 to 53.5). Neither baseline healthcare nor treatment was significantly associated with 'RA', but those who recovered were significantly more likely to report benefit from their baseline treatment (62% vs 0%, p<0.0001).
The results of the multivariate logistic regression showed that age > 50 years ( p=0.047) and a symmetrical distribution of symptoms at baseline (p<0.0001) were the only independent statistically significant factors associated with 'RA' at follow-up.
DISCUSSION
A median of 27.5 months after an epidemic of CHIKV on Mauritius, we found that 79% of adults infected were still experiencing musculoskeletal symptoms and that the symptoms were generally rated moderate or severe (>4/10 on a VAS for pain) and caused functional impairment. Chronicity was associated with older age and female gender and with symmetrical joint symptoms during the infection. Persistence was also associated with attendance at two or more healthcare providers during the acute illness. Of those with persistent symptoms, 10 subjects (5%) fulfilled modified 1987 ACR criteria for a diagnosis of 'RA'. These 10 subjects were older and all female. 'RA' was associated with age >50 years and symmetrical joint symptoms during the acute infection.
Our findings add to a growing body of evidence that CHIKV can be associated with long-term joint manifestations. 6 7 9-11 21 Our results also bear out those of studies that have described long-term polyarthritis similar to RA after CHIKV. 7 22 23 Although 5% of those infected is not a large proportion, this estimate may be conservative, since we were unable to undertake rheumatoid factor testing or radiographic investigation in the present study. Given the high infectivity in epidemic areas, CHIKV may become an increasingly important cause of chronic In our study, it did not appear that baseline treatment or response to that treatment was associated with outcomes. There was some suggestion in the univariate analyses that failure to respond to baseline treatment and attendance at more than two healthcare providers was associated with poorer prognosis. However, we could not demonstrate that one treatment or combination of treatments made a significant difference to outcomes. It is thought-provoking that attendance at more than two healthcare providers was a risk factor for persistence. This could possibly be a marker of severity of initial symptoms leading to multiple consultations. However, it is also potentially a public health issue. We suggest that further research is required to see if, for example, earlier versus later treatment or use of a more aggressive combination approach could change longerterm outcomes. It is possible that disease-modifying antirheumatic drugs may be useful in chronic destructive polyarthritis after CHIKV. 7 24 The findings of this study need to be considered alongside several limitations. First, this study was retrospective and relied on self-reported symptoms at both baseline and follow-up and recall of baseline treatments offered and treatment efficacy. It is possible that recall bias operated such that people with persistent symptoms recalled matters at baseline more accurately or more fully than those who recovered. In Mauritius, chikungunya serological testing is restricted and therefore the diagnosis of infection with CHIKV for this study relied on self-reported occurrence of at least two (and in almost everybody three) baseline symptoms from the classic triad of fever, joint pains and rash. Potentially, this could have resulted in the misclassification of a number of study participants. However, it is interesting to note that the rates of persistence of symptoms reported in this study are very similar to those found by investigators in other countries where serological confirmation had been attained. 25 26 Moreover, CHIKV has been reported to be very rarely (<5% of cases) asymptomatic. 18 If symptoms were misclassified in this study, we would have expected to have included some study participants who in fact did not have CHIKV at baseline but rather other viral infections, including, for example, dengue infection, which is not recognised to cause longer-term musculoskeletal problems.
Recruitment for this study was geographical. A specific region recognised to have had high levels of CHIKV occurrence was specifically targeted, and participants were sought from a number of settings. Patients were asked to participate in a healthcare survey, but there is a possibility of responder bias whereby those subjects who perceived themselves to have suffered with longer-term problems after their CHIKV infection were more likely to participate. Although this effect cannot be ignored, and may have led to a relative overestimate of the frequency of occurrence of long-term musculoskeletal symptoms after CHIKV, it should not have had a systematic effect on the proportion of symptomatic subjects who fulfilled the modified criteria for RA. Therefore, we believe that this study importantly quantifies the prevalence of RA-like symptoms more than 2 years after CHIKV and demonstrates that those with 'RA' are significantly more disabled than others with persistent musculoskeletal symptoms. Together, these findings justify further research into the longer-term effects of CHIKV on the musculoskeletal system.
Respondents to this study were predominantly female. Although there is evidence that women are more affected by severe CHIKV, the significant female preponderance in this study may have resulted from the sampling methods and this may restrict the generalisability of the findings. Although the research team made every effort to attend workplaces as well as non-work settings, it was easier to recruit women who were more frequently at health and village centres during working hours. While this may have affected the female/male participant rates, it should not have systematically affected the betweengender prevalence estimates of rates of persistence after 2 years unless there is reason to believe that men who recovered were more likely to take part in this study than men who did not recover and that this was systematically different from the female respondents. If anything, we would have expected the bias to work in the opposite direction so that men who recovered would have been less likely to participate, having recovered and returned to full-time work. However, we cannot rule this out as an influence on the apparent importance of female gender on prognosis, and more research including equal proportions of male subjects is warranted.
These data, together with those of other investigators, suggest that CHIKV causes significant long-term joint pain 6 and disability 26 27 in many of those infected and therefore highlights an important priority in public health terms in seeking to eradicate CHIKV globally. Furthermore, given the epidemiological data suggesting a slow but steady progression of CHIKV worldwide provoked by travel, urbanisation and climate change 6 and into European countries, 28 a higher profile for this infection both as a cause of acute and chronic musculoskeletal symptoms needs to be attained among physicians. Our results point to the importance of older age, female gender and symmetrical joint involvement at baseline as potential 'markers' of risk factors for both long-term persistence and 'RA'. 
Main messages
▸ Chikungunya virus which causes chikungunya fever is progressing globally. ▸ Chikungunya fever is associated with a high prevalence of persistent rheumatic symptoms. ▸ Persistence of joint symptoms is associated with older age at the time of infection, female gender and symmetrical distribution of joint infections in the acute phase.
Current research questions
▸ Further research is needed to determine whether early use of antirheumatic drugs is useful in at-risk patients. ▸ Longer-term follow-up of patients with chronic joint symptoms would be useful to determine the progression of the condition. ▸ The pathology of chronic joint symptoms in chikungunya fever needs to be researched further.
